DENOSUMAB SHARED CARE GUIDLINES
|
|
- Dylan Hill
- 6 years ago
- Views:
Transcription
1 DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Denosumab has been approved by NICE (NICE TA204). The recommended dose of denosumab is 60mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of the arm. Patients must be adequately supplemented with calcium and vitamin D. NB: Another preparation of denosumab (XGEVA ) is licensed for bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. This is outside of the scope of this guideline. LOCAL ENHANCED SERVICES FOR SHARED CARE DRUG MONITORING This drug has been assessed as level 2 shared care and will be commissioned as per LES and in accordance with the supporting local shared care prescribing documentation. For further guidance on commissioning levels and for referral letters see guidance document at Mid Essex website: For product information see SPC: Primary Prevention Denosumab will be recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures: and REFERRAL CRITERIA AND PATIENT SELECTION who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments who have a combination of T-score, age and number of independent clinical risk factors for fracture. (Independent clinical risk factors for fractures are parental history of hip fracture, alcohol intake of 4 units or more per day, and rheumatoid arthritis) and patients who have had bisphosphonate treatment for over 10 years. Secondary Prevention Denosumab will be recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments. Or if patients continue to have fractures while on bisphosphonates. DenosumabSCG201510v1.0.final Page 1 of 5
2 Use outside NICE guidelines Where NICE TA 204 is not applicable, i.e. because the patient is a man or a pre-menopausal woman, the specialist should affirm in the referral letter that the estimated 10-year fracture risk, or lifetime risk where life expectancy may be shorter than 10 years, is at least equivalent to, if not greater than, that envisaged in NICE TA 204. In such cases, patients may be managed under this shared care guideline and associated LES. INITIATION and MAINTENANCE Medication history is checked to ensure there are no contraindications to denosumab Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy Assess the patient to ensure he/she has good oral/dental hygiene. If necessary advise the patient to see a dentist before proceeding The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions Advise patients to seek prompt medical attention if they develop signs or symptoms of cellulitis Refer patients for prompt medical attention if they develop signs or symptoms of hypocalcaemia (i.e. altered mental status, tetany, seizures, and QTc prolongation) In line with MHRA drug safety update (February 2013) all patients newly initiated on denosumab therapy will be advised to report new or unusual thigh, hip or groin pain Doses are administered 6 monthly. The first dose will be administered in secondary care, after which the patient will be transferred to the GP for administration and monitoring of remaining injections The recommended dose of denosumab is 60mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or back of the arm Patients must be adequately supplemented with calcium and vitamin D. Calcium and vitamin D levels must be checked before each dose is administered. Before administration, the denosumab solution should be inspected Do not inject the solution if it contains particles, or is cloudy or discoloured Do not shake excessively To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room temperature (up to 25 C) before injecting a single subcutaneous injection into the thigh, abdomen or back of arm Inject slowly Inject the entire contents of the pre-filled syringe Any unused product or waste material should be disposed of in accordance with local requirements Corrected calcium (monitored prior to each dose unless advised otherwise by specialist) Vitamin D levels (monitored prior to each dose unless advised otherwise by specialist) egfr (monitored prior to each dose unless advised otherwise by specialist) ADMINISTRATION and DOSAGE 2.2 mmol/l despite patient adherence with supplementation < 50 nmol/l despite patient adherence with supplementation <30 ml/min/1.73m 2 or receiving dialysis team for advice team for advice team for advise on frequency of Ca 2+ monitoring (suggested pre and post injection monitoring) It is essential that the dosing frequency of every six months plus or minus two weeks is maintained for the duration of therapy DenosumabSCG201510v1.0.final Page 2 of 5
3 On-going Advise patients to seek prompt medical attention if they develop signs or symptoms of cellulitis Refer patients for prompt medical attention if they develop signs or symptoms of hypocalcaemia (i.e. altered mental status, tetany, seizures, and QTc prolongation). Hypocalcaemia with denosumab most commonly occurs within the first 6 months of dosing, but it can occur at any time during treatment Secondary care will retain responsibility for any further diagnostic tests e.g. DXA and/or bone turnover markers as deemed appropriate for the patient and will communicate any change in the treatment plan as a result of these tests with the GP in a timely way Other Adverse effects: MONITORING Below are some of the more common side effects, note that this list is NOT exhaustive and that it is recommended that the SPC (Link: ) and BNF should be consulted for a more comprehensive list. Common side effects include: urinary tract infection, upper respiratory tract infection, sciatica, cataracts, constipation, rash, pain in extremities Responsibilities of the Hospital To assess the suitability of the patient for denosumab To discuss the benefits and side effects of treatment with the patient Explain to the patient that the treatment is 6 monthly injections Advise the patient that their other osteoporosis treatments should stop but that they should continue with their calcium and vitamin D supplements; even normo-calcaemic patients could be at risk of hypocalcaemia following administration of denosumab if they are Vitamin D deficient Discuss the shared care arrangement with the patient and ensure he/she understands the plan for their follow-up 6 monthly injections at their GP surgery Explain to the patient that the GP will refer them back for a review on completion of the treatment course (as specified by the specialist) Assess the patient to ensure he/she has good oral hygiene and use clinical judgement to determine if dental examination is required prior to initiating therapy If concerned about oral health, advise patient to seek dental assessment and remedial dental care. Instruct patients under dental treatment or undergoing dental surgery, to tell their dentist that they are being treated with denosumab Administer first denosumab injection Report any adverse events to the MHRA Supply GP with a summary of the patient review including link to local guidelines on use of denosumab [The specialist should always state the rationale for prescribing denosumab in preference to other alternative bone protection drugs in the clinic letter] To determine need and frequency of monitoring of any further diagnostic tests e.g. DXA and/or bone turnover markers and to organise such tests and communicate any resulting change in treatment plan with the patient and their GP in a timely way DenosumabSCG201510v1.0.final Page 3 of 5
4 Responsibilities of the GP To ensure that denosumab is added to the patient's drug record To ensure that other osteoporosis treatments (e.g. alendronate, strontium) are stopped and removed from the patient's repeat prescription To ensure that calcium and vitamin D supplements are continued [Supplementation should be with at least calcium 700 mg daily and at least 800 units vitamin D daily] To ensure that advice is sought should hypocalcaemia develop despite adequate supplementation To ensure that additional monitoring (as advised by specialist) of serum calcium levels is conducted in patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis Ensure an account is set up to order denosumab and determine if it will come direct to the practice (more straightforward scenario for the patient). Alternatively, if the patient will need to collect their prescription from the pharmacy ensure an FP10 is supplied at least 2 weeks prior to planned injection date Advise patient that they may sign up to the company s patient support programme online should they wish to receive alerts and reminders Ensure that prior to injection the denosumab prefilled syringe must be kept in its outer carton, in order to protect from light, and stored in a refrigerator. Prescribe and administer the denosumab injection at six monthly intervals for time period as specified by the initiating specialist (a protocol on how to administer the injection is available from the company if required) Report any adverse events to the MHRA and discuss with the consultant if action is uncertain Refer patient back to the consultant for review on completion of the treatment course, or sooner if any concerns (such as anti-resorptive related osteonecrosis of the jaw, altered mental health, tetany, seizures, or QTc prolongation which may indicate severe hypocalcaemia) Refer back to the specialist if a new fracture occurs after 1 year of treatment (i.e. 2 doses) and especially if the fractures are multiple, e.g. multi-level vertebral fractures or multiple rib fractures as treatment failure may be suspected In line with MHRA drug safety update (February 2013) all patients newly initiated on denosumab therapy will be advised to report new or unusual thigh, hip or groin pain. Patients presenting with such symptoms to the GP should be referred for prompt medical attention for evaluation of an incomplete femoral fracture. Contacts - Consultants Details to be included in specialist s letter Pharmacy Medicines Information, Broomfield Hospital (Mon Fri 9am 5pm) DenosumabSCG201510v1.0.final Page 4 of 5
5 Title Denosumab Shared Care Guidelines Document reference DenosumabSCG201510v1.0.final Author Catherine Hamilton, Deputy Chief Pharmacist, MECCG Consulted with Dr Arul Srinivasan, Consultant Rheumatologist, MEHT Reference: n/a Approved by Mid Essex Medicines Management Committee Date approved October 2015 Next review date October 2017 Previous Version New Document Updates DenosumabSCG201510v1.0.final Page 5 of 5
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationBarts Health NHS Trust and local GPs Shared Care Guidelines. DENOSUMAB (Prolia) Post menopausal osteoporosis
Barts Health NHS Trust and local GPs Shared Care Guidelines Indication: DENOSUMAB (Prolia) Post menopausal osteoporosis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline the use of Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Author(s)/Originator(s):
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationPrescribing Framework for Denosumab (Prolia ) in Osteoporosis
Hull & East Riding Prescribing Committee Prescribing Framework for Denosumab (Prolia ) in Osteoporosis Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) Communication We agree
More informationAdding Prolia (denosumab) to EMIS PCS
Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS PCS Date of preparation October 2014 DMB-GBR-AMG-658-2014-P Amgen have fully funded the development, by Oberoi Consulting,
More informationAdding Prolia (denosumab) to EMIS Web
Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS Web Date of preparation September 2013 DMB-GBR-AMG-597-2013-P UK/DNB/0083c/13 37046242 Amgen & GSK have fully funded the
More informationDenosumab (Prolia ) (TLS Amber)
Denosumab (Prolia ) (TLS Amber) Shared Care Guidelines: For the treatment of postmenopausal osteoporosis. AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways
More informationPrescribing of Denosumab (Prolia ) in Wales: Review. Full document
Prescribing of Denosumab (Prolia ) in Wales: Review Full document October 2013 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory
More informationAdding Prolia (denosumab) to EMIS PCS
Prescribing information can be found on page 15 Adding Prolia (denosumab) to EMIS PCS Date of preparation July 2015 UKIE-P-162-0615-108159 Amgen have fully funded the development, by Oberoi Consulting,
More informationAdding Prolia (denosumab) to SystmOne
Prescribing information can be found on page 15 Adding Prolia (denosumab) to SystmOne Date of preparation September 2013 DMB-GBR-AMG-594-2013-P UK/DNB/0083/13 37046251 Amgen & GSK have fully funded the
More informationAdding Prolia (denosumab) to INPS Vision
Prescribing information can be found on page 15 Adding Prolia (denosumab) to INPS Vision Date of preparation September 2013 DMB-GBR-AMG-598-2013-P UK/DNB/0083d/13 37046239 Amgen & GSK have fully funded
More informationAdding Prolia (denosumab) to INPS Vision
Prescribing information can be found on page 19 Adding Prolia (denosumab) to INPS Vision Date of preparation July 2015 UKIE-P-162-0615-108161 Amgen have fully funded the development, by Oberoi Consulting,
More informationAdding Prolia (denosumab) to INPS Vision
Prescribing information can be found on page 19 Adding Prolia (denosumab) to INPS Vision Date of preparation October 2014 DMB-GBR-AMG-661-2014-P Amgen have fully funded the development, by Oberoi Consulting,
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationAdding Prolia (denosumab) to EMIS Web
Prescribing information can be found on page 19 Adding Prolia (denosumab) to EMIS Web Date of preparation: August 2017 UKIE-P-162-0616-031936(1) Amgen have fully funded the development, by Oberoi Consulting,
More informationAdding Prolia (denosumab) to SystmOne
Prescribing information can be found on page 19 Adding Prolia (denosumab) to SystmOne Date of preparation October 2014 DMB-GBR-AMG-662-2014-P Amgen have fully funded the development, by Oberoi Consulting,
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Issue date: October 2010 Denosumab for the prevention of osteoporotic fractures in postmenopausal women This guidance was developed using the single technology appraisal process NICE technology appraisal
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab for the prevention of osteoporotic fractures in Issued: October 2010 guidance.nice.org.uk/ta204 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationProlia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI)
Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) What is in this CMI What Prolia is used for When you must not be given it Taking other medicines How it is given Instructions
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationBisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday
Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for
More informationPROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More informationMAN SHORTER CAN MAKE A HOW OSTEOPOROSIS. Ask your doctor if you have osteoporosis and if Prolia may be right for you. AND WHAT YOU CAN DO NEXT
Ask your doctor if you have osteoporosis and if Prolia may be right for you. Prolia is a prescription medicine used to increase bone mass in men with osteoporosis who: are at high risk for fracture, meaning
More informationRheumatology Department Patient Information Leaflet. Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis.
Prolia (denosumab) Rheumatology Department Patient Information Leaflet Introduction Prolia (denosumab) is a treatment for post-menopausal osteoporosis. What is osteoporosis? Osteoporosis is a condition
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationProlia 2 shots a year proven to help strengthen bones. next shot appointment
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com next shot appointment For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia
More informationUnderstanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.
Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with
More informationProlia 2 shots a year proven to help strengthen bones.
For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven to help strengthen bones. Blythe Danner, Award winning actress taking Prolia. Prolia is
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in a pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationMPharm Programme. Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy
MPharm Programme Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy Louise.statham@sunderland.ac.uk Slide 1 of 47 MPHM13 Module Introduction Aims This lecture will build
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationProlia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI)
Prolia Denosumab(rch) den''-os''-u''-mab Consumer Medicine Information (CMI) What is in this CMI What Prolia is used for When you must not be given it Taking other medicines How it is given Instructions
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationFulvestrant (Faslodex )
In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR XGEVA. Notes
For prevention of skeletal-related events XGEVA is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention
More informationElements for a Public Summary
Ibandronat Stada 50 mg film-coated tablets Ibandronat Stada 150 mg film-coated tablets 3.11.2014, Version V2.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary
More informationTeriparatide (also known as Forsteo) Rheumatology Department Patient Information Leaflet
Teriparatide (also known as Forsteo) Rheumatology Department Patient Information Leaflet Introduction This information leaflet is about a medicine called teriparatide (also known as Forsteo) which is used
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationGuidelines on Management of Osteoporosis
Guidelines on Management of Osteoporosis Introduction These guidelines take into account recommendations from the DH Guidance on Falls and Fractures (Jul 2009), NICE Technology appraisals for Primary and
More informationProlia 2 shots a year proven to help strengthen bones.
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationPHARMACOLOGIC PROPERTIES
Denosumab Prolia TM 60mg/mL Solution for Injection PRODUCT DESCRIPTION Each pre-filled syringe contains 60 mg of denosumab in 1.0 ml solution (60 mg/ml). Clear, colourless to slightly yellow solution,
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationParathyroid Hormone Analogs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.36 Subject: Parathyroid Hormone Analogs Page: 1 of 6 Last Review Date: September 15, 2017 Parathyroid
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationPackage leaflet: Information for the user. Ibandroninezuur STADA 3 mg/3 ml, oplossing voor injectie. Ibandronic acid
Package leaflet: Information for the user Ibandroninezuur STADA 3 mg/3 ml, oplossing voor injectie Ibandronic acid Read all of this leaflet carefully before you start using this medicine because it contains
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPackage leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium
Package leaflet: Information for the patient Risedronate sodium 35 mg film-coated tablets Risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationWAHT- TWI Guidelines for Osteoporosis in Worcestershire.
GUIDELINES FOR OSTEOPOROSIS IN WORCESTERSHIRE This guidance does not override the individual responsibility of health professionals to make appropriate decisions according to the circumstances of the individual
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationYou have been referred to the osteoporosis clinic because you have sustained a fracture of the *hip / vertebra / wrist.
EXAMPLE 1a FRACTURE PATIENT INVITE LETTER «ClinicPhone» «PatientAddress1» «PatientAddress2» «PatientAddress3» «PatientAddress4» «PatientPostcode» Dear «PatientTitle» «PatientSurname» You have been referred
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationOral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Guidance in Brief
Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Guidance in Brief For further details, please refer to the full guidance, available at www.sdcep.org.uk March 2017
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More informationNAME OF THE MEDICINE. Prolia is the Amgen Inc. trademark for denosumab (rch). DESCRIPTION
Prolia (denosumab) Product Information Page 1 of 15 NAME OF THE MEDICINE Prolia is the Amgen Inc. trademark for denosumab (rch). DESCRIPTION Denosumab is a fully human IgG2 monoclonal antibody with high
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: denosumab_prolia_xgeva 3/2011 9/2017 9/2018 9/2017 Description of Procedure or Service Receptor activator
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More information